Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

Overview of attention for article published in Cost Effectiveness and Resource Allocation, October 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#47 of 433)
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet

blogs: 1 blog

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 63 Mendeley

Summary News Blogs Dimensions citations

So far, Altmetric has seen 1 news story.

Nusinersen Passes Cost-Effectiveness Thresholds for Infantile-Onset SMA

AJMC, 30 Oct 2020

A study assessing the cost effectiveness of nusinersen (Spinraza)—approved in December 2016—compared with best supportive case (B…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.